drugset / Trial / NCT05745532
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
NaSingle-groupOpen-labelTreatment
Summary
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
Timeline
- Start
- 2020-12-01
- Primary completion
- 2025-05-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | β-globin restored autologous hematopoietic stem cells | Cell therapy | — | — |